GSTP1polymorphism predicts treatment outcome and toxicities for breast cancer
| Autor: | Yang Liu, Shao-Liang Zhu, Jie Ma, Xiangyang Huang, Danke Su |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Gastroenterology 03 medical and health sciences GSTP1 breast cancer 0302 clinical medicine Breast cancer Internal medicine medicine Chemotherapy business.industry toxicities Hazard ratio Odds ratio medicine.disease Confidence interval Surgery meta-analysis Radiation therapy 030104 developmental biology Oncology 030220 oncology & carcinogenesis Meta-analysis treatment outcome business |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.18513 |
| Popis: | // Jie Ma 1, * , Shao-Liang Zhu 2, * , Yang Liu 3, * , Xiang-Yang Huang 1 and Dan-Ke Su 1 1 Department of Radiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China 2 Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China 3 Department of Radiotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China * These authors contributed equally to this work Correspondence to: Dan-Ke Su, email: doctorsu0771@sina.com Keywords: GSTP1, breast cancer, treatment outcome, toxicities, meta-analysis Received: October 07, 2016 Accepted: May 23, 2017 Published: June 16, 2017 ABSTRACT This study aimed to investigate the association of the GSTP1 gene polymorphism with the outcomes and toxicities of treatments in breast cancer. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the association of GSTP1 polymorphism with tumour response and toxicities, and the hazard ratios (HRs) and 95% CIs were calculated for the association between GSTP1 polymorphism and overall survival (OS). The statistical analysis showed that the GSTP1 polymorphism was not associated with tumour response or OS. A significant increase in the incidence of toxicities was observed (GA vs . AA OR = 1.45, 95% CI = 1.04–2.01, P = 0.028; GG vs . AA OR = 1.47, 95% CI = 1.03–2.10, P = 0.036; recessive model OR = 1.54, 95% CI = 1.13–2.09, P = 0.006; and allele model OR = 1.35, 95% CI = 1.07–1.71, P = 0.011), especially in the chemotherapy ± surgery group (GA vs . AA OR = 1.64, 95% CI = 1.05–2.56, P = 0.030; recessive model OR = 1.72, 95% CI = 1.17–2.54, P = 0.006; and allele model OR = 1.57, 95% CI = 1.11–2.21, P = 0.010). Our results indicate that the GSTP1 polymorphism may be associated with increased toxicity, especially in patients treated with chemotherapy ± surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|